We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster
Read MoreHide Full Article
Moderna (MRNA - Free Report) announced that the European Medicines Agency accepted its conditional marketing authorization (CMA) application seeking approval to use a 50-µg booster dose of its bivalent BA.4/BA.5 Omicron-targeting COVID-19 vaccine, mRNA-1273.222, in individuals 12 years of age and older.
This bivalent vaccine is a combination of 25-µg Spikevax (mRNA-1273), Moderna’s currently marketed COVID vaccine and 25-µg of another vaccine candidate targeting the Omicron BA.4 and BA.5 subvariants.
The filing is supported by data based on preclinical studies conducted on mRNA-1273.222 and data from the phase II/III study, which evaluated mRNA-1273.214, another bivalent candidate developed by Moderna to target the Omicron BA.1 subvariant.
The phase II/III study on the Omicron BA.1 targeting vaccine has achieved all its primary endpoints. Data from the study showed that a 50-µg dose of mRNA-1273.214 generated superior antibodies against the Omicron variant compared with those who received a 50-µg booster dose of Spikevax. mRNA-1273.214 (irrespective of prior infection or age) also generated potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared with those who received abooster dose of Spikevax.
Shares of Moderna have declined 51.9% so far this year compared with the industry’s 28.0% fall.
Image Source: Zacks Investment Research
Earlier this month, the European Commission (EC) authorized mRNA-1273.214 as well as Pfizer (PFE - Free Report) /BioNTech’s (BNTX - Free Report) Omicron BA.1-adapted bivalent vaccine for use in individuals aged 12 years and above.
The authorization for the BA.1 targeted bivalent boosters came in anticipation of a surge in COVID-19 infections in the upcoming winter. The original vaccines developed by Pfizer/BioNTech and Moderna helped countries combat the pandemic in record time. However, their lack of efficacy against emerging variants of the virus was a concern. Hence, the regulatory bodies had urged the COVID-19 vaccine makers to advance a bivalent vaccine candidate to make an Omicron-adapted vaccine available to various countries as soon as possible.
On Sep 12, the EC authorized Pfizer/BioNTech’s Omicron BA.4/BA.5-adapted bivalent vaccine in individuals aged 12 years and older. Pfizer/BioNTech have also submitted a variation to the marketing authorization for the BA.4/BA.5-adapted bivalent vaccine earlier this week, seeking to expand the use of the booster vaccine to include children aged 5 through 11 years.
This August, the FDA granted emergency use authorization (EUA) to Pfizer/BioNTech and Moderna’s Omicron BA.4/BA.5-adapted bivalent vaccines for a single booster dose. The Pfizer/BioNTech and Moderna booster vaccines can be given at least two months following primary or booster vaccination. While Moderna’s Omicron booster is authorized for use in adults aged 18 years and older, Pfizer/BioNTech’s version is approved for people 12 and older.
In the past 60 days, estimates for Morphic’s 2022 loss per share have narrowed from $3.38 to $1.80. Loss estimates for 2023 have narrowed from $3.91 to $3.62 during the same period. Shares of Morphic have lost 39.3% in the year-to-date period.
Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster
Moderna (MRNA - Free Report) announced that the European Medicines Agency accepted its conditional marketing authorization (CMA) application seeking approval to use a 50-µg booster dose of its bivalent BA.4/BA.5 Omicron-targeting COVID-19 vaccine, mRNA-1273.222, in individuals 12 years of age and older.
This bivalent vaccine is a combination of 25-µg Spikevax (mRNA-1273), Moderna’s currently marketed COVID vaccine and 25-µg of another vaccine candidate targeting the Omicron BA.4 and BA.5 subvariants.
The filing is supported by data based on preclinical studies conducted on mRNA-1273.222 and data from the phase II/III study, which evaluated mRNA-1273.214, another bivalent candidate developed by Moderna to target the Omicron BA.1 subvariant.
The phase II/III study on the Omicron BA.1 targeting vaccine has achieved all its primary endpoints. Data from the study showed that a 50-µg dose of mRNA-1273.214 generated superior antibodies against the Omicron variant compared with those who received a 50-µg booster dose of Spikevax. mRNA-1273.214 (irrespective of prior infection or age) also generated potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared with those who received abooster dose of Spikevax.
Shares of Moderna have declined 51.9% so far this year compared with the industry’s 28.0% fall.
Image Source: Zacks Investment Research
Earlier this month, the European Commission (EC) authorized mRNA-1273.214 as well as Pfizer (PFE - Free Report) /BioNTech’s (BNTX - Free Report) Omicron BA.1-adapted bivalent vaccine for use in individuals aged 12 years and above.
The authorization for the BA.1 targeted bivalent boosters came in anticipation of a surge in COVID-19 infections in the upcoming winter. The original vaccines developed by Pfizer/BioNTech and Moderna helped countries combat the pandemic in record time. However, their lack of efficacy against emerging variants of the virus was a concern. Hence, the regulatory bodies had urged the COVID-19 vaccine makers to advance a bivalent vaccine candidate to make an Omicron-adapted vaccine available to various countries as soon as possible.
On Sep 12, the EC authorized Pfizer/BioNTech’s Omicron BA.4/BA.5-adapted bivalent vaccine in individuals aged 12 years and older. Pfizer/BioNTech have also submitted a variation to the marketing authorization for the BA.4/BA.5-adapted bivalent vaccine earlier this week, seeking to expand the use of the booster vaccine to include children aged 5 through 11 years.
This August, the FDA granted emergency use authorization (EUA) to Pfizer/BioNTech and Moderna’s Omicron BA.4/BA.5-adapted bivalent vaccines for a single booster dose. The Pfizer/BioNTech and Moderna booster vaccines can be given at least two months following primary or booster vaccination. While Moderna’s Omicron booster is authorized for use in adults aged 18 years and older, Pfizer/BioNTech’s version is approved for people 12 and older.
Moderna, Inc. Price
Moderna, Inc. price | Moderna, Inc. Quote
Zacks Rank & Key Pick
Moderna currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Morphic (MORF - Free Report) , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Morphic’s 2022 loss per share have narrowed from $3.38 to $1.80. Loss estimates for 2023 have narrowed from $3.91 to $3.62 during the same period. Shares of Morphic have lost 39.3% in the year-to-date period.
Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%.